JP2013511534A5 - - Google Patents

Download PDF

Info

Publication number
JP2013511534A5
JP2013511534A5 JP2012540047A JP2012540047A JP2013511534A5 JP 2013511534 A5 JP2013511534 A5 JP 2013511534A5 JP 2012540047 A JP2012540047 A JP 2012540047A JP 2012540047 A JP2012540047 A JP 2012540047A JP 2013511534 A5 JP2013511534 A5 JP 2013511534A5
Authority
JP
Japan
Prior art keywords
use according
medicament
psoriasis
brimonidine
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012540047A
Other languages
English (en)
Japanese (ja)
Other versions
JP5680660B2 (ja
JP2013511534A (ja
Filing date
Publication date
Priority claimed from US12/621,942 external-priority patent/US8394800B2/en
Application filed filed Critical
Publication of JP2013511534A publication Critical patent/JP2013511534A/ja
Publication of JP2013511534A5 publication Critical patent/JP2013511534A5/ja
Application granted granted Critical
Publication of JP5680660B2 publication Critical patent/JP5680660B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012540047A 2009-11-19 2010-11-18 乾癬を治療または予防するためのα２アドレナリン受容体作動薬の使用 Expired - Fee Related JP5680660B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/621,942 2009-11-19
US12/621,942 US8394800B2 (en) 2009-11-19 2009-11-19 Method for treating psoriasis
PCT/US2010/057184 WO2011075267A1 (en) 2009-11-19 2010-11-18 Use of alpha 2 adrenergic receptor agonists for treating or preventing psoriasis

Publications (3)

Publication Number Publication Date
JP2013511534A JP2013511534A (ja) 2013-04-04
JP2013511534A5 true JP2013511534A5 (enExample) 2013-06-27
JP5680660B2 JP5680660B2 (ja) 2015-03-04

Family

ID=43729952

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012540047A Expired - Fee Related JP5680660B2 (ja) 2009-11-19 2010-11-18 乾癬を治療または予防するためのα２アドレナリン受容体作動薬の使用

Country Status (13)

Country Link
US (2) US8394800B2 (enExample)
EP (1) EP2501373B1 (enExample)
JP (1) JP5680660B2 (enExample)
KR (2) KR101374907B1 (enExample)
CN (1) CN102844025B (enExample)
AU (1) AU2010332233C1 (enExample)
BR (1) BR112012012131A2 (enExample)
CA (1) CA2781112C (enExample)
ES (1) ES2532527T3 (enExample)
MX (1) MX2012005790A (enExample)
NZ (1) NZ600333A (enExample)
RU (1) RU2538729C2 (enExample)
WO (1) WO2011075267A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
RU2535008C2 (ru) 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
MX2012010824A (es) 2010-03-26 2012-10-10 Galderma Res & Dev Metodos y composiciones mejoradas para tratamiento seguro y efectivo del eritema.
US8492422B2 (en) * 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol for treating skin diseases and conditions
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
SG189896A1 (en) 2010-10-21 2013-06-28 Galderma Sa Brimonidine gel compositions and methods of use
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013016072A1 (en) * 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
US9861645B2 (en) 2012-12-28 2018-01-09 Rak Holdings Llc Anti-itch scalp treatment compositions and combinations
US20140350106A1 (en) * 2013-05-22 2014-11-27 Professional Compounding Centers Of America Urea Silicone Gel for Scars and Hydration Treatment and Method of Using Same
WO2016052947A1 (ko) * 2014-09-29 2016-04-07 (주)네오팜 건성 치료용 산성 외용제 조성물
US20220211672A1 (en) * 2019-05-01 2022-07-07 Clexio Biosciences Ltd. Methods of treating pruritus
BR112021020962A2 (pt) 2019-05-01 2021-12-14 Clexio Biosciences Ltd Métodos de tratamento de prurido

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278447A (en) * 1963-12-02 1966-10-11 Cloro Bac Products Inc Process for stabilizing chlorine dioxide solution
US3560501A (en) * 1966-09-15 1971-02-02 Ciba Geigy Corp Process for making dihydroquinazolines
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
BE766039A (fr) * 1971-04-21 1971-09-16 Labofina Sa Nouveaux polymeres contenant des unites de pyrazole et procede de preparation de ces polymeres.
US3740442A (en) * 1972-01-14 1973-06-19 Sandoz Ag 2-isopropylaminobenzophenones in treating inflammation
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5166331A (en) * 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
FR2648709A1 (fr) 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5198442A (en) * 1989-10-12 1993-03-30 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5204347A (en) * 1989-10-12 1993-04-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) tetrahydroquinoxalines
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5237072A (en) * 1990-02-06 1993-08-17 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5130441A (en) * 1990-02-06 1992-07-14 Allergan, Inc. Method for producing amino-2-imidazoline derivatives
US5721237A (en) * 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5736165A (en) * 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ES2187533T3 (es) * 1993-10-13 2003-06-16 Allergan Inc Usdo de derivados de (2-imidazolin-2-ilamino)quinoxalina.
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
WO1996013267A2 (en) 1994-10-27 1996-05-09 Allergan Combinations of prostaglandins and brimonidine or derivatives thereof for the treatment of glaucoma
US5693646A (en) * 1994-12-22 1997-12-02 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5720962A (en) * 1995-10-04 1998-02-24 Au Pharmaceuticals, Inc. Analgesic lotion for hemorrhoids and method of making such lotion
US6441047B2 (en) * 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
JP2001512471A (ja) 1997-02-21 2001-08-21 バイヤースドルフ・アクチエンゲゼルシヤフト しゅさの処置のための調製物
US6159944A (en) * 1998-02-27 2000-12-12 Synchroneuron, Llc Method for treating painful conditions of the anal region and compositions therefor
ES2220257T1 (es) * 1998-03-11 2004-12-16 Kabushiki Kaisha Soken Agentes normalizadores para la piel.
US6432934B1 (en) * 1998-08-06 2002-08-13 Advanced Vision Research Methods and compositions for topical treatment of eye surface inflammation and related dry eye disease
US20030087962A1 (en) * 1998-10-20 2003-05-08 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US20020197300A1 (en) * 1999-02-22 2002-12-26 Schultz Clyde L. Drug delivery system for anti-glaucomatous medication
AU5331200A (en) 1999-06-11 2001-01-02 Ohio State University Research Foundation, The Methods and compositions for treating raynaud's phenomenon and scleroderma
US6147102A (en) * 1999-10-26 2000-11-14 Curatek Pharmaceuticals Holding, Inc. Clonidine preparations
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6284765B1 (en) * 2000-04-27 2001-09-04 The University Of North Texas Health Science Center At Fort Worth (+) naloxone and epinephrine combination therapy
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7211267B2 (en) * 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
AU2002256471B2 (en) * 2001-05-03 2007-05-24 Allergan, Inc. Compositions having enhanced pharmacokinetic characteristics
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US6680062B2 (en) * 2001-10-05 2004-01-20 Color Access, Inc. Anti-irritating rosacea treatment
US20040266776A1 (en) 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20040092482A1 (en) * 2002-11-07 2004-05-13 Gupta Shyam K. Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions
US20040156873A1 (en) * 2003-02-10 2004-08-12 Gupta Shyam K. Topically Bioavailable Acne and Rosacea Treatment Compositions
US20040220259A1 (en) * 2003-04-04 2004-11-04 Yu Ruey J. Topical treatment of dermatological disorders associated with reactive or dilated blood vessels
WO2004103233A1 (en) * 2003-05-15 2004-12-02 Cutanix Corporation Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7141597B2 (en) * 2003-09-12 2006-11-28 Allergan, Inc. Nonsedating α-2 agonists
US20050059664A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Novel methods for identifying improved, non-sedating alpha-2 agonists
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
BRPI0414277A (pt) * 2003-09-12 2006-11-07 Allergan Inc métodos e composições para o tratamento de dor e outras condições mediadas adrenérgicas alfa 2
US7285544B2 (en) * 2003-11-18 2007-10-23 Bernstein Eric F Use of nitroxides in treating skin disease
US7239705B2 (en) 2003-12-10 2007-07-03 Motorola Inc. Apparatus and method for broadcast services transmission and reception
WO2005070465A2 (en) 2004-01-14 2005-08-04 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
CA2567401C (en) * 2004-05-25 2013-11-12 Sansrosa Pharmaceutical Development, Inc. Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
US8158161B2 (en) * 2005-01-12 2012-04-17 S.U.L.V.E. Ltd. Methods and pharmaceutical compositions useful for treating psoriasis
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
WO2007103687A2 (en) * 2006-03-01 2007-09-13 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
PT2252290T (pt) * 2008-02-15 2018-02-14 Bone Therapeutics Sa Composição farmacêutica para utilização no tratamento e/ou prevenção de doenças osteoarticulares
EP2090307A1 (en) 2008-02-15 2009-08-19 Bone Therapeutics Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
JP5728234B2 (ja) * 2008-02-15 2015-06-03 ボーン・セラピューティクス 骨関節疾患の治療又は予防において使用するための医薬組成物
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition

Similar Documents

Publication Publication Date Title
JP2013511534A5 (enExample)
ES2368974T3 (es) Preparación que contiene osmolitos para uso en caso de membranas mucosas secas.
JP2668800B2 (ja) 皮膚疾患の局所治療
US20120264818A1 (en) Topical Compositions with Cannabis Extracts
US20130072532A1 (en) Topical transdermal dexmedetomidine compositions and methods of use thereof
JP2011529038A5 (enExample)
JP2009280627A5 (enExample)
US11382900B2 (en) Composition for preventing or treating sleep disorders
WO2008019213A2 (en) Use of extracts for the treatment of viral disorders
WO2009053741A3 (en) Novel formulation
US20200093785A1 (en) Skin care compositions and methods
US20130274321A1 (en) Topical Compositions with Cannabis Extracts
CN107670027B (zh) 治疗皮肤病况的组合物和方法
US20190105335A1 (en) Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
JP2016517882A5 (enExample)
Bhanusali et al. Treatment outcomes for tinea capitis in a skin of color population
ES2551614T3 (es) Uso de alcoholes pegilados para el tratamiento de la queratosis actínica
EP1888174B1 (en) Use of chalcones for the treatment of viral disorders
WO2024239066A1 (en) Pharmaceutical composition
CN103458928B (zh) (r)-1,2-丙二醇用作治疗性冷却剂组合物中的溶剂
WO2005037275A1 (en) Topical compositions comprising telmesteine for treating dermatological disorders
JPWO2019002421A5 (enExample)
RU2011121659A (ru) Депигментирующие местные композиции и их применение
ITUB20159582A1 (it) Composizione, per uso topico, utile per la prevenzione di disturbi di tipo infiammatorio e/o infettivo delle mucose.
JP2017088559A (ja) フィラグリン産生促進剤